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Back to school for malaria prevention: a new tool in the era 
of malaria elimination?
Children and pregnant women are at increased risk of 
malaria. Among children, research to date has focused 
on preschool children (aged <5 years) because this 
age group has the highest malaria death and illness 
rates of malaria illness and deaths. With changing 
malaria endemicity, however, vulnerability patterns 
among children of different age groups might change.1 
Furthermore, children aged 5–15 years predominantly 
have the highest risk of asymptomatic malaria and 
gametocytaemia, and yet low use of long-lasting 
insecticide treated nets, which puts them at risk.1,2 As 
part of global efforts to reduce and eliminate malaria 
transmission, it is only logical to find effective malaria 
prevention strategies for school children.
Prevention strategies such as intermittent preventive 
treatment have been recommended for pregnant 
women, infants, and, in Sahelian countries, children 
younger than 5 years as part of seasonal malaria 
chemoprevention. Currently, there is no WHO 
recommendation for malaria prevention among 
school children in sub-Saharan Africa. The systematic 
review by Lauren Cohee and colleagues3 offers the 
first comprehensive review and meta-analyses of the 
effects of different prevention strategies on outcomes 
in school children. School malaria prevention 
programmes in 13 included studies showed reduced 
asymptomatic (11 studies) and clinical malaria by 
approximately 50% (4 studies), and reduced anaemia 
by 15% (11 studies), whereas there was a marginal 
effect on cognitive function in children above 10 
years (5 studies). These improvements in the health 
and academic performance in children are impressive. 
Furthermore, some trials reported a reduction in 
gametocytaemia in the intervention group4,5 and 
one study6 noted a small but significant reduction in 
community transmission. These results deserve review 
by policy makers to identify what further evidence 
is needed before recommending school-based 
malaria programmes, and discussion with national 
programmes on how school-based strategies might be 
funded and implemented.
Further evidence might be needed on the effects of 
malaria treatment on cognitive ability using different 
types of cognitive tests, and on the effects of school 
treatment and school holidays (without treatment) 
on malaria transmission in the community and child 
health. Cost-effectiveness analyses to help national 
malaria programmes assess cost-benefits would also be 
useful in addition to guidance on factors important for 
selecting the type of intervention. Most studies included 
in the review used some form of intermittent preventive 
treatment. The only study which used screening and 
treatment did not show a reduction in parasitaemia;7 
indeed, trials on screen and treat strategies in pregnancy 
trials also showed no clear advantage over intermittent 
preventive treatment for pregnant women.8 As Cohee 
and colleagues point out, rapid diagnostic malaria 
tests might not be sensitive enough to detect malaria. 
Further considerations are that a strategy that does not 
use rapid diagnostic malaria tests simplifies training, 
reduces the risks of taking blood and reduces cost. 
Chemotherapy, used in one older study, was effective 
but requires adherence.
When considering intermittent preventive treatment, 
malaria transmission and seasonality will inform 
frequency of dosing or the timing of the doses, as in 
seasonal malaria chemoprevention. Beneficial effects 
of intermittent preventive treatment in children were 
seen in areas of low and high low transmission, but 
reductions in Plasmodium falciparum parasitaemia 
was higher when using drugs with longer prophylactic 
effects. In the high transmission setting of Côte 
d’Ivoire, three-monthly sulfadoxine–pyrimethamine 
alone (ie, not in combination with other drugs) did not 
show a beneficial effect on P falciparum parasitaemia,9 
which is somewhat surprising given the low levels of 
sulfadoxine–pyrimethamine resistance in west Africa.10 
It is likely that the frequency of dosing (three-monthly) 
was insufficient because of the high re-infection rates 
observed. To achieve a protective dose of intermittent 
preventive treatment in high transmission areas, 
monthly doses with drug combinations with at least one 
drug with a long half-life might be needed, whereas less 
frequent doses are required in areas of low transmission. 
In areas of seasonal malaria, a dose given at the end of 
the rainy season appears to go a long way.5
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Combination therapies seem effective and could 
reduce the development of drug resistance; however, 
studies and programmes need to consider the choice 
of drug in the context of national first-line treatment 
policy to safeguard first-line malaria therapies. There 
were no reports of any new adverse events in any of 
the included studies that reported on side-effects. 
How well malaria prevention school programmes will 
work in real-life settings has not been assessed, and 
feasibility and acceptability studies, which address 
adherence, are needed. Lessons should be learned from 
treatment of pregnant women; after almost 30 years 
of implementation of a one-dose drug, coverage with 
intermittent preventive treatment for pregnant 
women is far from optimal.11 We should learn from 
other prevention strategies such as seasonal malaria 
chemoprevention, which has been successful in 
achieving high rates of coverage.11 Importantly, malaria 
preventive strategies in schools will have health and 
educational benefits for children and can also contribute 
to reductions in community transmission. That is a goal 
worth fighting for.
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